PUBLIC COMPANY
save$NBIXNEUROCRINE BIOSCIENCES INC
$NBIX152.72+1.26%San Diego, CA, USupdated 17h ago
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
community read0 votes
pipeline
6
marketed
2
phase 3
2
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(6)
pipeline depth6 products
1Preclinical2Phase 32Marketed1Unknown
Marketed
VALBENAZINE TOSYLATE
Chorea
Marketedcrinecerfont
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
Phase 3direclidine citrate
Schizophrenia
Phase 3hydrocortisone MR
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
PreclinicalNBIP-2118
Obesity
drugINGREZZA SPRINKLE
1 INDICATIONS AND USAGE INGREZZA and INGREZZA SPRINKLE ar…
Synaptic vesicular amine transporter
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase3NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- phase2A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
- phase3Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
- phase2Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
- phase3Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- phase2Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
- phase3NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- phase2Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Insider activity
source: SEC Form 4routine RSU / option mechanics (2)
- Mar 4, 26giftABERNETHY MATT · Chief Financial Officer2,249 sh
- Feb 20, 26giftOnyia Jude · Chief Scientific Officer3,110 sh
🐶 Hiring Signal
next earnings Oct 28, 2026
News
- STAT+: PBMs agree to display TrumpRx drug pricesBristol's Zenbexus wins accelerated approval, Novartis wins UK patent fight over Entresto, and more biotech news from The Readoutstat · 22h ago
- STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classThe FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.stat · 1d ago
- STAT+: Commure terminates payments under its customer referral programs tied to AI productsCommure, which develops and sells AI products to clinics, has terminated a program that paid for referrals to new customers.stat · 1d ago
- STAT+: Eli Lilly targets booming black market for retatrutideKhartis raises oral immunology funds, Neurocrine drug safety concerns, and more biotech news from The Readoutstat · 1d ago
- STAT+: Neurocrine Biosciences and the delicate balance of benefit and riskWhen it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.stat · 2d ago
- Four questions on new safety warnings for Neurocrine’s Vykat XRA group of experts on Prader-Willi syndrome has sounded the alarm on side effects and deaths that may be connected to Neurocrine Biosciences’ medicine Vykat XR. The treatment has been linked to sev…endpoints · 2d ago
- Deaths reported after treatment with Neurocrine’s approved Prader-Willi drugReports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day f…biospace · 2d ago
- STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and moreEli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutidestat · 3d ago
- STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trialDefinium Therapeutics said that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials.stat · 3d ago
- STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapiesGerman researcher Georg Schett has made a name for himself as a pioneer in autoimmune disease treatment. Now he's co-founding his own company.stat · 3d ago
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that